EFFICIENCY OF PATHOGENETIC THERAPY OF PATIENTS WITH ISCHEMIC HEART DISEASE WITH INTESTINAL DYSBIOSIS AND NORMOBIOTSENOZOM

Ischemic heart disease (IHD) is the main reason of cardiovascular mortality in Ukraine rates of which are not decreased. The aim of the study – to learn the effectiveness of standard pathogenetic therapy of patients with ischemic heart disease with normobiotsenozom (NB) and dysbiosis (DB) gut. Materials and Methods. The study involved 68 patients aged 50 to 65 years, including 20 % of women. Patients with IHD with postinfarction cardiosclerosis, chronic heart failure (CHF) II functional class (FC) (NYHA) and intestinal dysbiosis of the 1st and 2nd degree (n = 45) and patients comparable by gender, age, FC CHF group ( n = 23) of the intestine normobiotsenozom received standard treatment of chronic coronary artery disease. The duration of follow-up was 8 weeks. Results and Discussion. We established standard therapy positive effect on the clinical course of the disease, lipid metabolism and lipid peroxidation, indicators of immune inflammation, systemic inflammatory response and antioxidant in both groups of patients. It was found that the presence of intestinal dysbiosis of the 1st and 2nd levels associated with a lesser degree of positive dynamics in most of these parameters. Conclusions. The standard therapy of patients with ischemic heart disease with normobiocenosis and intestinal dysbiosis of the 1st and 2nd degrees accompanied by a positive impact on the clinical course of disease in a reduction in the number of angina attacks per week, increasing the distance test of 6–minute walking and improved psychological status.